Associated Papers
Nuclear force transmission drives cancer-associated fibroblast activation under BRAF inhibition.
Wang J et al.
Biorxiv : the Preprint Server for Biology, 2025
AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis.
Kim H et al.
Cell Death & Disease, 2022
35585049 (PubMed )
Supplement: 41419_2022_4921_MOESM1_ESM.docx
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
31668570 (PubMed )
Supplement: mmc4.xlsx › Sheet1
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
Yao Z et al.
Nature Medicine, 2019
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.
Sun Y et al.
Neuro-oncology, 2017
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
Yao Z et al.
Cancer Cell, 2015
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Girotti MR et al.
Cancer Cell, 2015
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
Wagenaar TR et al.
Pigment Cell & Melanoma Research, 2014
ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP et al.
Oncogene, 2013
Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Vergani E et al.
Neoplasia (new York, N.y.), 2011
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.
Whittaker S et al.
Cancer Research, 2010
Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
Whittaker S et al.
Science Translational Medicine, 2010
Select a paper to view details